Industry to FDA: No Evidence of Liver Disease or Elevated Liver Function in CBD Study Participants
– Hemp Industry Daily
Global Widget™, the trusted powerhouse behind top-selling CBD brands Hemp Bombs®, Nature’s Script™ and Perfect Paws Hemp™ for pets, is one of 12 companies whose customers participated in a groundbreaking human-safety study on Hemp-derived CBD consumption and liver toxicity. The early results show no evidence of liver toxicity or disease in the 839 participants.
The FDA commissioned the study in its push to better understand CBD’s safety and efficacy. ValidCare – a Denver-based medical research firm specializing in patient-centered clinical trials – provided the results that observed potential liver effects in adults who used oral forms of Hemp-derived CBD for at least 60 days.
“The safety, efficacy and quality of our products is our No. 1 priority,” said Margaret Richardson, Global Widget’s chief compliance and legal officer. “As the FDA readies its guidance for the CBD industry and Hemp-derived CBD products, it is imperative that science-based data such as this be presented so the administration can issue proper regulatory guidance in the months ahead.”
ValidCare’s partnerships with national laboratories have allowed the company to deliver timely results from each brand to FDA officials within six weeks.
“We are excited for our principal investigators to continue, expand and report out on this foundational work in the next few months,” Validcare CEO Patrick McCarthy said.
Read Hemp Industry Daily’s full release regarding the CBD liver study and Global Widget’s involvement here.
March 25, 2021